Genedx Holdings Corp. (WGS) Stock Price & Analysis
Genedx Holdings Corp. (WGS) fell 6.75% to USD 59.1 as of July 25, 2026 at 19:40 UTC, according to Nexqual real-time market data.
WGS last closed at USD 63.38; the session ranged USD 58.97–64.91 on volume of 429,145 shares. Market capitalization is $1.75B, with a 52-week range of USD 32.21–170.87 (NMS). Source: Nexqual, July 25, 2026 at 19:40 UTC.
Key Statistics (as of July 25, 2026 at 19:40 UTC)
| Price | USD 59.1 |
|---|---|
| Change | ▼ 6.75% (down) |
| Previous Close | USD 63.38 |
| Open | USD 63.93 |
| Day Range | USD 58.97 – 64.91 |
| 52-Week Range | USD 32.21 – 170.87 |
| Volume | 429,145 shares |
| Market Cap | $1.75B |
| Exchange | NMS |
Technical Analysis (WGS)
Nexqual's technical model rates WGS "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 19:40 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.44 (neutral) |
| vs SMA50 | Above (USD 57.65) |
| MACD | 0.32 (positive) |
Analyst Ratings (WGS)
Wall Street analysts rate WGS "Strong Buy" based on 9 analysts, with a mean price target of USD 81.78 (range USD 63–100), per Nexqual as of July 25, 2026 at 19:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 81.78 |
| High Target | USD 100 |
| Low Target | USD 63 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (WGS)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $111.01M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.28 vs est -0.02 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.12 ▲ beat |
| 2025-09-30 | USD 0.49 vs est 0.42 ▲ beat |
| 2025-06-30 | USD 0.5 vs est 0.11 ▲ beat |
Source: Nexqual, July 25, 2026 at 19:40 UTC.
Financials & Fundamentals (WGS)
| Total Revenue | $442.68M |
|---|---|
| Revenue Growth (YoY) | +17.40% |
| Gross Margin | +69.56% |
| Operating Margin | -25.61% |
| Profit Margin | -17.58% |
| ROE | -30.42% |
| Debt / Equity | 66.19 |
| Current Ratio | 3.09 |
| Total Cash | $170.68M |
| Total Debt | $168.19M |
| Free Cash Flow | $3.64M |
Source: Nexqual, July 25, 2026 at 19:40 UTC.
Financial Health Score (WGS)
Nexqual rates Genedx Holdings Corp.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 19:40 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 70%, operating -26% |
| Balance Sheet | Strong — $171M cash vs $168M debt, net cash position |
| Cash Flow | Mixed — FCF $4M, slim 0.9% margin |
| Efficiency | Critical — ROE -30%, ROA -4.4% |
Ownership (WGS)
| Insider Ownership | +12.31% |
|---|---|
| Institutional Ownership | +115.40% |
| Shares Outstanding | 29.69M |
| Float | 18.94M |
| Short % of Float | +37.75% |
Source: Nexqual, July 25, 2026 at 19:40 UTC.
Leadership (WGS)
Genedx Holdings Corp. is led by Katherine A. Stueland (age 49), CEO & Director, per Nexqual as of July 25, 2026 at 19:40 UTC.
| CEO & Director | Katherine A. Stueland (age 49) |
|---|---|
| Chief Financial Officer | Kevin Feeley (age 44) |
| Chief Technology & Innovation Officer | Bryan M. Dechairo (age 52) |
| President | Mark A. Gardner (age 59) |
| Director of Investor Relations & Communications | Sabrina V. Dunbar |
Major Backers & Investors (WGS)
Notable institutional backers of Genedx Holdings Corp. include Corvex Management LP, Casdin Capital, LLC, ARK Invest, according to Nexqual as of July 25, 2026 at 19:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Corvex Management LP | 10.87% |
| Casdin Capital, LLC | 10.13% |
| ARK Invest | 9.03% |
| Westfield Capital Management Co LP | 4.61% |
| Goldman Sachs | 4.5% |
| Oracle Investment Management Inc | 2.98% |
| William Blair Investment Management, LLC | 2.61% |
| Zweig-Dimenna Associates LLC | 2.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.76% |
| Vanguard Group | 5.72% |
Source: Nexqual, July 25, 2026 at 19:40 UTC.
From Genedx Holdings Corp.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses.
- To achieve these objectives, we: • Deploy our team of approximately 120 field-based sales representatives and medical science liaisons, and construct an industry-leading brand, product, marketing, communications and market access platform that leverages our expertise, rich data, and decades of earned trust across the genetics community. • Partner with leaders across health systems, manufacturers, commercial and governmental payors and advocacy groups.
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, these steps may be circumvented, or third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- We are also applying AI tools – like our machine learning powered gene ranker, Multiscore – on top of GeneDx Infinity TM to harness the power of our data, scale our platform and increase speed and turnaround time.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SEZL | Sezzle Inc. | USD 153.89 | ▼ 11.68% |
| NTRA | Natera, Inc. | USD 261.99 | ▼ 0.84% |
| GRAL | GRAIL, Inc. | USD 67.84 | ▼ 3.99% |
| SMMT | Summit Therapeutics Inc. | USD 13.66 | ▼ 7.33% |
| JANX | Janux Therapeutics, Inc. | USD 15.33 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 19:40 UTC. This page is informational and not investment advice.